Double Blind Randomized Phase III Controlled Trial Comparing the Effect of Intraperitoneal Nebulization of Ropivacaine With Intraperitoneal Instillation of Ropivacaine on Pain Control After Laparoscopic Cholecystectomy
Overview
- Phase
- Phase 3
- Status
- Completed
- Sponsor
- San Gerardo Hospital
- Enrollment
- 60
- Locations
- 1
- Primary Endpoint
- Postoperative Pain
Overview
Brief Summary
Studies evaluating intraperitoneal local anesthetic instillation for pain relief after laparoscopic procedures have provided conflicting results. This randomized, double-blind study was designed to assess the effects of a novel intraperitoneal local anesthetic administration technique using nebulization on pain relief after laparoscopic cholecystectomy.
Detailed Description
Studies evaluating intraperitoneal local anesthetic (LA) instillation for pain relief after laparoscopic cholecystectomy have provided conflicting results. One of the factors that might contribute to failure of the instillation technique may be related to inadequate distribution of local anesthetic throughout the peritoneal surface. In contrast, nebulization should provide a uniform spread of drugs throughout the peritoneal cavity and thus may be beneficial to improve pain relief after laparoscopic procedures. A recent study reported that bupivacaine nebulization significantly reduced pain after laparoscopic cholecystectomy compared with bupivacaine instillation in the gallbladder bed. However, these investigators used a custom-made nebulization system that needs a separate gas source and tubing that is cumbersome and may not be easily available.
Recently, the investigators reported that a microvibration-based nebulization device (Aeroneb Pro® system, Aerogen, Galway, Ireland) could be used for ropivacaine delivery into the insufflation gas required to create pneumorpeitoneum. The investigators hypothesized that intraperitoneal ropivacaine nebulization would provide superior pain relief after laparoscopic cholecystectomy than intraperitoneal ropivacaine instillation. This randomized, double blind, controlled clinical trial was designed to assess the analgesic efficacy of ropivacaine nebulization using the Aeroneb Pro® device laparoscopic cholecystectomy compared with intraperitoneal ropivacaine instillation.
Study Design
- Study Type
- Interventional
- Allocation
- Randomized
- Intervention Model
- Parallel
- Primary Purpose
- Treatment
- Masking
- Triple (Participant, Investigator, Outcomes Assessor)
Eligibility Criteria
- Ages
- 18 Years to 70 Years (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •ASA Score I-III
- •Scheduled for laparoscopic cholecystectomy
- •Free from pain in preoperative period
- •Not using analgesic drugs before surgery
- •Without cognitive impairment or mental retardation
- •Written informed consent
Exclusion Criteria
- •Emergency/urgency surgery
- •Postoperative admission in an intensive care unit
- •Cognitive impairment or mental retardation
- •Progressive degenerative diseases of the CNS
- •Seizures or chronic therapy with antiepileptic drugs
- •Severe hepatic or renal impairment
- •Pregnancy or lactation
- •Allergy to one of the specific drugs under study
- •Acute infection or inflammatory chronic disease
- •Alcohol or drug addiction
Arms & Interventions
Instillation
Instillation of Ropivacaine 100 mg in the abdominal cavity
Intervention: Ropivacaine 100 mg (Drug)
Nebulization
Nebulization of Ropivacaine 60 mg in the abdominal cavity
Intervention: Ropivacaine 60 mg (Drug)
Outcomes
Primary Outcomes
Postoperative Pain
Time Frame: 48 hours
Postoperative pain was assessed by Visual analgue scale (VAS 0 to 100 points) at rest (static VAS) and after a deep inspiration or cough (dynamic VAS). The proportion of patients with adequate pain control after surgery (dynamic VAS \< 3) will also be assessed.
Secondary Outcomes
- Morphine consumption (mg)(Up to 48 hours)
- Time of unassisted walking(Up to 48 hours)
- Hospital morbidity(Up to 48 hours)
- Time to hospital discharge(48 hours)